Скачать или смотреть Just the Facts: Noxopharm

Noxopharm Ltd (ASX:NOX) is seeking to shift the treatment paradigm for autoimmune diseases and especially lupus, advancing its SOF-SKN first-in-class oligonucleotide TLR7/8 antagonist in a bid to fully treat the disease, rather than just manage symptoms.

Proactive’s Tylah Tully details the company’s new phase 1 HERACLES study in the latest #JustTheFacts, which will transition into a follow-on trial targeting the treatment of lupus patients at a number of specialist centres in Australia.

“At the big picture level, we very much see this as just the first chapter in developing the Sofra platform across larger markets,” Noxopharm CEO Dr Gisela Mautner said.

“We will make decisions with these ambitions in mind while continuing to introduce the huge potential of the platform to external stakeholders.”

Read more about the HERACLES study on our website
https://ow.ly/nb3g50T0OVb

#Biotech #Biopharmaceuticals #AutoImmuneDisease #Lupus #ASX #NOX#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews